Compare CRGO & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CRGO | ACOG |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | Spain | Canada |
| Employees | 382 | 57 |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.9M | 110.4M |
| IPO Year | N/A | N/A |
| Metric | CRGO | ACOG |
|---|---|---|
| Price | $2.00 | $6.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.40 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 89.9K | 38.5K |
| Earning Date | 05-26-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.61 | $139.22 |
| Revenue Next Year | $16.85 | $134.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $4.50 |
| 52 Week High | $4.24 | $10.88 |
| Indicator | CRGO | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 46.61 |
| Support Level | $1.96 | $5.00 |
| Resistance Level | $2.20 | $6.59 |
| Average True Range (ATR) | 0.12 | 0.42 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 64.52 | 28.62 |
Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters, thousands of forwarders, and dozens of airlines and ocean carriers. The company operates in two segments: the Platform segment and the Solutions segment. The majority of the revenue is derived from the Solutions segment, which provides software tools and data to help industry participants automate their pricing, sales, and procurement processes. Geographically, it generates the maximum revenue from Europe, and the rest from the United States, Hong Kong and Others.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.